Free Trial

Fulgent Genetics (FLGT) Stock Forecast & Price Target

Fulgent Genetics logo
$18.42 -0.74 (-3.86%)
(As of 11/13/2024 ET)

Fulgent Genetics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
2
Buy
0

Based on 2 Wall Street analysts who have issued ratings for Fulgent Genetics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 2 analysts, 2 have given a hold rating for FLGT.

Consensus Price Target

$28.50
54.72% Upside
According to the 2 analysts' twelve-month price targets for Fulgent Genetics, the average price target is $28.50. The highest price target for FLGT is $35.00, while the lowest price target for FLGT is $22.00. The average price target represents a forecasted upside of 54.72% from the current price of $18.42.
Get the Latest News and Ratings for FLGT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Fulgent Genetics and its competitors.

Sign Up

FLGT Analyst Ratings Over Time

TypeCurrent Forecast
11/14/23 to 11/13/24
1 Month Ago
10/15/23 to 10/14/24
3 Months Ago
8/16/23 to 8/15/24
1 Year Ago
11/14/22 to 11/14/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
2 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$28.50$30.00$30.00$39.33
Forecasted Upside54.72% Upside47.42% Upside27.61% Upside43.87% Upside
Consensus Rating
Hold
Hold
Hold
Moderate Buy
Why buying gold might be a mistake (Ad)

Something strange just happened with gold. With the recent Fed rate cut… My charts are showing a breakout signal I haven't seen in years. But for now, I'm not rushing to buy gold. In fact, I'm telling everyone I know to hold off. Because I believe there’s a far better way to play this upcoming surge. It's a method that could turn a 1% gold price change into gains like 59%, 118%, or even 228%. And it doesn't involve buying a single ounce of physical gold or even buying any regular gold stock. I've been trading gold for nearly 20 years now and this is my #1 recommended approach for trading gold right now. Most traders miss them completely… But for those who know how to spot them, it takes their trades to a whole new level.

If you're interested, check out the recording here while the link's still up.

FLGT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

FLGT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Fulgent Genetics Stock vs. The Competition

TypeFulgent GeneticsMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.80
2.50
Consensus RatingHoldModerate BuyHold
Predicted Upside48.59% Upside26,392.09% Upside7.84% Upside
News Sentiment Rating
Neutral News

See Recent FLGT News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/11/2024Piper Sandler
2 of 5 stars
 Lower TargetNeutral ➝ Neutral$26.00 ➝ $22.00+13.23%
12/7/2023UBS Group
4 of 5 stars
 Initiated CoverageNeutral$35.00+31.98%
3/2/2023Credit Suisse Group
3 of 5 stars
 Lower TargetOutperform$50.00 ➝ $45.00+41.29%
11/18/2022Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$45.00+25.38%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 10:28 PM ET.


FLGT Forecast - Frequently Asked Questions

According to the research reports of 2 Wall Street equities research analysts, the average twelve-month stock price forecast for Fulgent Genetics is $28.50, with a high forecast of $35.00 and a low forecast of $22.00.

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" FLGT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FLGT, but not buy additional shares or sell existing shares.

According to analysts, Fulgent Genetics's stock has a predicted upside of 54.72% based on their 12-month stock forecasts.

Fulgent Genetics has been rated by research analysts at Piper Sandler in the past 90 days.

Analysts like Fulgent Genetics less than other "medical" companies. The consensus rating for Fulgent Genetics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how FLGT compares to other companies.


This page (NASDAQ:FLGT) was last updated on 11/13/2024 by MarketBeat.com Staff
From Our Partners